Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: Peak concentration/MIC versus area under the curve/MIC ratios

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 9, 2003, Pages 2749-2755

  Scaglione, F ^a,c   Mouton, J W ^b   Mattina, R ^a   Fraschini, F ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BACTERIAL PNEUMONIA; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG PROTEIN BINDING; FEMALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; SURVIVAL; TREATMENT OUTCOME;

ANIMALS; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; CIPROFLOXACIN; COLONY COUNT, MICROBIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; PNEUMONIA, PNEUMOCOCCAL; PROTEIN BINDING; STREPTOCOCCUS PNEUMONIAE; SURVIVAL ANALYSIS;

EID: 0042925343     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.9.2749-2755.2003     Document Type: Article

References (35)

1. Ambrose, P. G., D. M. Grasela, T. H. Grasela, J. Passarell, H. B. Mayer, and P. F. Pierce. 2001. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob. Agents Chemother. 45:2793-2797.
2. Andes, D. R., and W. A. Craig. 1998. Pharmacodynamics of fluoroquinolones in experimental models of endocarditis. Clin. Infect. Dis. 27:47-50.
3. Bakker-Woudenberg, I. A., J. C. van den Berg, T. B. Vree, A. M. Baars, and M. F. Michel. 1985. Relevance of serum protein binding of cefoxitin and cefazolin to their activities against Klebsiella pneumoniae pneumonia in rats. Antimicrob. Agents Chemother. 28:654-659.
4. Bedos, J. P., E. Azoulay-Dupuis, P. Moine, M. Muffat-Joly, B. Veber, J. J. Pocidalo, and E. Vallee. 1998. Pharmacodynamic activities of ciprofloxacin and sparfloxacin in a murine pneumococcal pneumonia model: relevance for drug efficacy. J. Pharmacol. Exp. Ther. 286:29-35.
5. Bedos, J. P., V. Rieux, J. Bauchet, M. Muffat-Joly, C. Carbon, and E. Azoulay-Dupuis. 1998. Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model. Antimicrob. Agents Chemother. 42:862-867.
6. Blaser, J., B. B. Stone, M. C. Groner, and S. H. Zinner. 1987. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob. Agents Chemother. 31:1054-1060.
7. Cars, O. 1990. Pharmacokinetics of antibiotics in tissues and tissue fluids: a review. Scand. J. Infect. Dis. Suppl. 74:23-33.
8. Craig, W. A. 1998. Choosing an antibiotic on the basis of pharmacodynamics. Ear Nose Throat J. 77(Suppl. 6):7-11.
9. Craig, W. A., and S. C. Ebert. 1989. Protein binding and its significance in antibacterial therapy. Infect. Dis. Clin. N. Am. 3:407-414.
10. Drusano, G. L., D. E. Johnson, M. Rosen, and H. C. Standiford. 1993. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob. Agents Chemother. 37:483-490.
11. Drusano, G. L., S. L. Preston, R. C. Owens, Jr., and P. G. Ambrose. 2001. Fluoroquinolone pharmacodynamics. Clin. Infect. Dis. 33:2091-2096.
12. Fernandez, J., J. F. Barrett, L. Licata, D. Amaratunga, and M. Frosco. 1999. Comparison of efficacies of oral levofloxacin and oral ciprofloxacin in a rabbit model of a staphylococcal abscess. Antimicrob. Agents Chemother. 43:667-671.
13. Forrest, A., D. E. Nix, C. H. Ballow, T. F. Goss, M. C. Birmingham, and J. J. Schentag. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37:1073-1081.
14. Forrest, A., S. Chodosh, M. A. Amantea, D. A. Collins, and J. J. Schentag. 1997. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. J. Antimicrob. Chemother. 40(Suppl. A):45-57.
15. Friis, C. 1993. Penetration of danofloxacin into the respiratory tract tissues and secretions of calves. Am. J. Vet. Res. 54:1122-1127.
16. Greco, C. 2003. Tissue cages in calves for studies on pharmacokinetic/pharmcodynamic relationships of antimicrobials. Ph.D. thesis. Swedish University of Agricultural Sciences, Uppsala, Sweden.
17. Highet, V. S., A. Forrest, C. H. Ballow, and J. J. Schentag. 1999. Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacy. J. Antimicrob. Chemother. 43(Suppl. A):55-63.
18. Lacy, M. K., W. Lu, X. Xu, P. R. Tessier, D. P. Nicolau, R. Quintiliani, and C. H. Nightingale. 1999. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob. Agents Chemother. 43:672-677.
19. Leggett, J. E., S. Ebert, B. Fantin, and W. A. Craig. 1990. Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models. Scand. J. Infect. Dis. Suppl. 74:179-184.
20. Lister, P. D., and C. C. Sanders. 1999. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. J. Antimicrob. Chemother. 43:79-86.
21. Lister, P. D., and C. C. Sanders. 1999. Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. Antimicrob. Agents Chemother. 43:1118-1123.
22. MacGowan, A., and K. Bowker. 2002. Developments in PK/PD: optimising efficacy and prevention of resistance. A critical review of PK/PD in in vitro models. Int. J. Antimicrob. Agents 19:291-298.
23. MacGowan, A. P., C. A. Rogers, H. A. Holt, M. Wootton, and K. E. Bowker. 2001. Pharmacodynamics of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model of infection. Antimicrob. Agents Chemother. 45:2916-2921.
24. Madaras-Kelly, K. J., B. E. Ostergaard, L. B. Hovde, and J. C. Rotschafer. 1996. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 40:627-632.
25. a.Marchbanks, C. R., J. R. McKiel, D. H. Gilbert, N. J. Robillard, B. Painter, S. H. Zinner, and M. N. Dudley. 1993. Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro model of infection. Antimicrob. Agents Chemother. 37:1756-1763.
26. Mattie, H. 1978. Tissue penetration of antibiotics. Pharmacokinetic aspects of tissue penetration. Scand. J. Infect. Dis. Suppl. 14:125-126.
27. Mouton, J. W., M. N. Dudley, O. Cars, H. Derendorf, and G. L. Drusano. 2002. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. Int J. Antimicrob. Agents 19:355-358.
28. National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
29. Ng, W., I. Lutsar, L. Wubbel, F. Ghaffar, H. Jafri, G. H. McCracken, and I. R. Friedland. 1999. Pharmacodynamics of trovafloxacin in a mouse model of cephalosporin-resistant Streptococcus pneumoniae pneumonia. J. Antimicrob. Chemother. 43:811-816.
30. Onyeji, C. O., K. Q. Bui, R. C. Owens, Jr., D. P. Nicolau, R. Quintiliani, and C. H. Nightingale. 1999. Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia. Int. J. Antimicrob. Agents 12:107-114.
31. Preston, S. L., G. L. Drusano, A. L. Berman, C. L. Fowler, A. T. Chow, B. Dornseif, V. Reichl, J. Natarajan, and M. Corrado. 1998. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 279:125-129.
32. SAS Institute, Inc. 1993. SAS user's guide. SAS Institute, Inc., Cary, N.C.
33. Schentag, J. J., K. K. Gilliland, and J. A. Paladino. 2001. Reply. Clin. Infect. Dis. 33:2092-2096.
34. Schentag, J. J., K. K. Gilliland, and J. A. Paladino. 2001. What have we learned from pharmacokinetic and pharmacodynamic theories? Clin. Infect. Dis. 32(Suppl. 1):S39-S46.
35. Wong, F. A., S. J. Juzwin, and S. C. Flor. 1997. Rapid stereospecific high-performance liquid chromatographic determination of levofloxacin in human plasma and urine. J. Pharm. Biomed. Anal. 15:765-771.